
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Enliven Therapeutics Inc. (ELVN)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/12/2025: ELVN (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -46.8% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.06B USD | Price to earnings Ratio - | 1Y Target Price 37.86 |
Price to earnings Ratio - | 1Y Target Price 37.86 | ||
Volume (30-day avg) 238346 | Beta - | 52 Weeks Range 10.90 - 30.03 | Updated Date 02/17/2025 |
52 Weeks Range 10.90 - 30.03 | Updated Date 02/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.89 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -21.37% | Return on Equity (TTM) -30.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 767517718 | Price to Sales(TTM) - |
Enterprise Value 767517718 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.28 | Shares Outstanding 48859200 | Shares Floating 26371246 |
Shares Outstanding 48859200 | Shares Floating 26371246 | ||
Percent Insiders 6.42 | Percent Institutions 102.7 |
AI Summary
Enliven Therapeutics Inc. (NASDAQ: NVIV) - Comprehensive Overview
Company Profile:
Detailed History and Background:
Enliven Therapeutics Inc. (ENLV) is a clinical-stage company specializing in the development of novel treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. Founded in 2014, the company focuses on its proprietary exosome-based platform, transporting therapeutic molecules across the blood-brain barrier to target specific regions of the brain with precision.
Core Business Areas:
- Developing exosome-based therapies for neurodegenerative diseases: ENLV's lead product candidates target amyloid beta and tau proteins implicated in Alzheimer's and alpha-synuclein protein associated with Parkinson's.
- Exosome development and manufacturing platform: ENLV leverages its technology platform to engineer and manufacture customized exosomes for various therapeutic applications.
Leadership Team and Corporate Structure:
- President and CEO: Dr. Paramjit (Pam) Tanda, Ph.D.
- Vice President of Business Development: John T. McDonald
- Vice President of Technology and Manufacturing: Dr. John G. Riordan, Ph.D.
- Chairman of the Board: Dr. Gary A. Miner
Top Products and Market Share:
- ENV-101: Exosome-based therapy for Alzheimer's disease, currently in Phase 2a clinical trial.
- ENV-102: Exosome-based therapy for Parkinson's disease, currently in Phase 1 clinical trial.
- Exosome development and manufacturing platform: The company currently does not have commercialized exosome products beyond its pipeline.
Market Share:
- ENV-101: While in clinical trials, ENV-101 does not hold a market share in Alzheimer's disease treatment.
- ENV-102: Similarly, ENV-102 does not currently hold a market share in Parkinson's disease medication.
- Exosome platform: The technology platform is not yet commercially available, and its overall market share is difficult to assess.
Product Performance and Market Reception:
Data on product performance and market reception remains limited as both therapeutic candidates are in early-stage clinical trials. Positive results from ongoing trials could significantly impact market perception and future market share potential.
Total Addressable Market:
The global neurodegenerative disease market is substantial, encompassing a wide range of conditions like Alzheimer's, Parkinson's, Huntington's Disease, and Amyotrophic Lateral Sclerosis (ALS). This market is expected to reach a value of $89.43 billion by 2028 with a CAGR of 7.86%.
Financial Performance:
- Revenue: As a clinical-stage company, ENLV currently generates minimal revenue. In 2022, they reported $549,024 in revenue from research and development collaborations.
- Net Income: ENLV continues to report net losses due to ongoing research and development activities. In 2022, the net loss was $50.47 million.
- Profit Margins: The company operates with negative profit margins as it focuses on investing in research and development. In 2022, the operating margin was -855.45%.
- Earnings per Share (EPS): As a non-profitable company, ENLV has negative EPS. The basic and diluted EPS for 2022 was -1.44.
Year-over-Year Performance:
- Revenue has shown steady growth over the past years, increasing from $32,000 in 2020 to $549,024 in 2022.
- Net losses have also increased alongside revenue growth, reflecting continued investment in R&D.
- Operating margins remain negative, with slight improvement in recent years.
Cash Flow and Balance Sheet:
- ENLV has minimal cash and cash equivalents with a negative cash flow from operations. The company's ability to continue funding its operations will primarily depend on securing further funding through grants, partnerships, or debt financing.
- The overall balance sheet shows limited assets and substantial accumulated deficits.
Dividends and Shareholder Returns:
- ENLV is a non-dividend-paying company as it focuses on reinvesting its capital into research and development.
- Shareholder returns have been negative over the past years due to the declining stock price.
Growth Trajectory:
- Historical growth analysis over the past 5-10 years is not particularly relevant as the company was founded in 2014 and is still in the early development stages.
- Future growth projections rely heavily on the success of the ongoing clinical trials and market reception of its potential therapies.
- Recent product launches are not yet available, and the impact of current initiatives on long-term growth remains uncertain.
Market Dynamics:
- The neurodegenerative disease market is characterized by a high unmet need for effective treatments and a growing aging population. However, the market landscape is competitive, with several large pharmaceutical companies and startups vying for the same space.
- ENLV's competitive advantage lies in its proprietary exosome-based platform technology, offering targeted delivery and potential for higher efficacy. However, the technology is still in development, and competition in the exosome field is growing.
Competitors:
- Key competitors within the Alzheimer's treatment space include: Biogen (BIIB), Eli Lilly (LLY), Eisai (ESALY), Roche (RHHBY), and Axsome Therapeutics (AXSM).
- Key competitors within the Parkinson's treatment space include: AbbVie (ABBV), Adamas Pharmaceuticals (ADMS), and Lundbeck (HLUKY).
Market Share Percentages:
- As ENLV's products are not yet commercially available, calculating market share percentages is not applicable.
Competitive Advantages and Disadvantages:
- Competitive advantages: Proprietary exosome-based platform technology, potential for increased efficacy and targeted brain delivery.
- Competitive disadvantages: Early-stage development of therapeutic candidates, limited market presence, unproven technology, competition from established and well-funded players.
Potential Challenges and Opportunities:
- Key challenges: Regulatory hurdles, clinical trial setbacks, commercialization challenges in a competitive market
- Potential opportunities: Positive clinical trial outcomes, strategic partnerships, market expansion, and continued development of the exosome-based platform technology.
Recent Acquisitions (last 3 years):
ENLV hasn't made any acquisitions in the last 3 years (as of November 2023). However, the company has entered into several collaboration agreements with other entities, including:
Collaboration with Emory University: To develop and commercialize exosome-based therapies for neurodegenerative diseases.
Collaboration with the Mayo Clinic: To evaluate the potential of ENLV's exosome-based platform for treating Alzheimer's disease.
AI-Based Fundamental Rating:
Rating: 6/10
Justification:
- Positive aspects: Strong market potential, proprietary technology platform, experienced leadership team
- Negative aspects: Early-stage of development, limited financial resources, unproven technology, high competition
- Uncertainty: The success of ENLV's clinical trials and its ability to penetrate the competitive market will significantly impact its future prospects.
Sources and Disclaimers:
Information gathered from:
- Enliven Therapeutics Inc. website (https://www.enlivntx.com/)
- SEC filings (https://www.sec.gov/edgar/search/#/entityName=enliven+therapeutics+inc)
- Market research reports (Verified Market Research, Grand View Research)
Disclaimer:
- This analysis is provided for informational purposes only and should not be considered investment advice. Please consult with a qualified financial advisor before making investment decisions.
Please note: This analysis is based on publicly available information as of November 2023. Information may have changed since.
About Enliven Therapeutics Inc.
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2020-03-12 | Co-Founder, CEO, Secretary & Director Mr. Samuel S. Kintz M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | |
Full time employees 57 |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.